A comparison of 67Cu‐ and 131I‐labelled forms of monoclonal antibodies SEN7 and SWA20 directed against small‐cell lung cancer

The intact anti‐SCLC monoclonal antibody (MAb) SEN7 and its F(ab')2 were labelled with the β‐emitting isotope 67Cu. Both materials retained their biological activity in vitro as determined by the Lindmo assay. In a direct comparison of in vivo distribution in a xenograph model, 131I‐ and 67Cu‐labelled intact SEN7 showed similar absolute tumour accumulation. Blood levels were markedly lower in the case of the 67Cu‐labelled antibody, resulting in improved tumour:blood ratios which reached a maximum of 13:1 compared with only 4.5:1 for 131I‐SEN7. In the case of the 67Cu‐labelled F(ab')2, very high accumulation of the nuclide was observed in the kidney. Levels of radio copper in liver and spleen were also found to be significantly raised when compared with radio iodine. SWA20, a MAb which had previously failed to show any selective in vivo accumulation in tumour xenografts when labelled with radio iodine showed higher and more stable tumour accumulation when labelled with 67Cu.

[1]  P. Schubiger,et al.  Preclinical evaluation of 67Cu-labeled intact and fragmented anti-colon carcinoma monoclonal antibody MAb35. , 1993, Cancer research.

[2]  R. Stahel,et al.  Anti‐tumor activity of a blocked ricin immunotoxin with specificity against the cluster‐5A antigen associated with human small‐cell lung cancer , 1993, International journal of cancer.

[3]  R. Stahel,et al.  Monoclonal antibody SEN7 recognizes a new epitope on the neural cell adhesion molecule present on small cell lung cancer but not on lymphocytes. , 1993, Cancer research.

[4]  G Sgouros,et al.  Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  M J Welch,et al.  Copper-64-labeled antibodies for PET imaging. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  T. Kaden,et al.  Antibody labeling with copper-67 using the bifunctional macrocycle 4-[(1,4,8,11-tetraazacyclotetradec-1-yl)methyl]benzoic acid. , 1991, Bioconjugate chemistry.

[7]  R. Stahel,et al.  Selective immunotherapy of small cell cancer xenografts using 131I-labelled SWA11 antibody. , 1991, British Journal of Cancer.

[8]  D. Scheinberg,et al.  A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Kunz,et al.  186Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice. , 1991, Cancer research.

[10]  R. Stahel,et al.  Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen. , 1990, British Journal of Cancer.

[11]  S. Anderson,et al.  Inhibition of catabolism of radiolabeled antibodies by tumor cells using lysosomotropic amines and carboxylic ionophores. , 1990, Cancer research.

[12]  G. Denardo,et al.  Radiation treatment of B cell malignancies with immunoconjugate. , 1990, Frontiers of radiation therapy and oncology.

[13]  D. Milenic,et al.  Comparison of methods for the generation of immunoreactive fragments of a monoclonal antibody (B72.3) reactive with human carcinomas. , 1989, Journal of immunological methods.

[14]  R. Stahel,et al.  Immunolocalisation and imaging of small cell cancer xenografts by the IgG2a monoclonal antibody SWA11. , 1989, British Journal of Cancer.

[15]  M. Unger,et al.  Scintigraphy with In-111-labeled monoclonal antitumor antibodies: kinetics, biodistribution, and tumor detection. , 1988, Radiology.

[16]  A. Vaughan,et al.  Radioimmunotherapy of cancer: clinical studies and limiting factors. , 1987, Cancer treatment reviews.

[17]  T. Kaden,et al.  Metal complexes with macrocyclic ligands. Part XXV. One‐step synthesis of mono‐N‐substituted azamacrocycles with a carboxylic group in the side‐chain and their complexes with Cu2+ and Ni2+ , 1986 .

[18]  J L Humm,et al.  Dosimetric aspects of radiolabeled antibodies for tumor therapy. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  R. Stahel,et al.  Murine monoclonal antibody LAM2 defines cell membrane determinant with preferential expression on human lung small‐cell carcinoma and squamous‐cell carcinomas , 1985, International journal of cancer.

[20]  M. Trucco,et al.  1 – Determination of Equilibrium Binding Parameters of Monoclonal Antibodies Specific for Cell Surface Antigens , 1981 .